Riskpilot← Back to searchSign inGet full accessSalient Pharma ApS
APSActiveCVR 36900709Naverland 22Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20151 employeeswww.salientpharma.com
Revenue 2024
DKK -124K
-47% vs 2023
EBITDA margin
100.0%
+47% vs 2023
Equity ratio
-5917.4%
Financial strength
Net profit 2024
DKK -202K
+34% vs 2023
| Revenue | DKK -124K | -47% |
| EBITDA | DKK -124K | +47% |
| Net profit | DKK -202K | +34% |
| Total assets | DKK 19K | -8% |
| Equity | DKK -1,1M | +3% |
| Employees | 1 | — |
Legal name
Salient Pharma ApS
CVR number
36900709
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
21. maj 2015
Share capital
DKK 419.920
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af et bestyrelsesmedlem og en direktør i forening.
Company purpose
Selskabets formål er at udøve virksomhed med udvikling, fremstilling samt markedsføring af produkter inden for life-science området samt dertil knyttede aktiviteter
Address
Naverland 22
Phone
+4542806300
Email
us@salientpharma.com
Website
www.salientpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | -955 | -1.244 | -838 | -730 | -485 | -259 | -126 | -233 | -124 |
| Staff expenses | -0 | -0 | -0 | -0 | -597 | -403 | -2 | -0 | -0 | -0 |
| EBITDA | 0 | -955 | -1.244 | -838 | -1.327 | -888 | -261 | -126 | -233 | -124 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | -955 | -1.244 | -838 | -1.327 | -888 | -261 | -126 | -233 | -124 |
| Net financials | 0 | -5 | 0 | -73 | 310 | -14 | -40 | -63 | -72 | -78 |
| Profit before tax | 0 | -960 | -1.244 | -910 | -1.647 | -902 | -301 | -188 | -305 | -202 |
| Tax | -0 | -187 | -274 | -200 | 713 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 0 | -772 | -971 | -710 | -2.360 | -902 | -301 | -188 | -305 | -202 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 592 | 399 | 2.856 | 579 | 45 | 55 | 58 | 21 | 19 |
| Equity | 0 | -847 | -1.818 | 2.769 | 410 | -492 | -793 | -981 | -1.161 | -1.126 |
| Long-term debt | 0 | 0 | 0 | 0 | 32 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 1.440 | 2.217 | 87 | 137 | 537 | 848 | 1.039 | 1.181 | 1.145 |
| Total debt | 0 | 1.440 | 2.217 | 87 | 169 | 537 | 848 | 1.039 | 1.181 | 1.145 |
EBITDA margin
-12437200.0%
This company
15.8%
Market median
-78716556% vs market
20152024
Equity ratio
-5917.4%
This company
38.2%
Market median
-15591% vs market
20152024
Return on equity
-20218000.0%
This company
18.4%
Market median
-109880535% vs market
20152024
Net profit margin
-20218000.0%
This company
8.1%
Market median
-249605038% vs market
20152024
Asset turnover
-6.54×
This company
1.12×
Market median
-684% vs market
20152024
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20152024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-05-21 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
US Management | Management | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
HB-MEDICAL HOLDING ApS | Company | 33.3% | 33.3% | 2023 |
SPORCON LIFESCIENCE ADVISORS ApS | Company | 25.0% | 25.0% | 2023 |
CAND.PHARM. POVL M. ASSENS FOND | Company | 15.0% | 15.0% | 2023 |
Kjær Henningsen Holding ApS | Company | 5.0% | 5.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HB-MEDICAL HOLDING ApS
Salient Pharma ApS Board members of Salient Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulrik Spork | Management | 0 companies |
| Søren Wang Petersen | Board of Directors | 0 companies |
| Helle Bøwadt | Board of Directors | 0 companies |
| Søren Johannes Kjær Henningsen | Board of Directors | 0 companies |